{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:39:54Z","timestamp":1793295594631,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.euros.2026.09.005","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:48:28Z","timestamp":1791265708000},"page":"56-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Expression of NECTIN-4 and TROP-2 in Resected Upper Tract Urothelial Carcinoma with and Without Preoperative Chemotherapy"],"prefix":"10.1016","volume":"93","author":[{"given":"Leticia C.","family":"Clemente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Igel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse T.R.","family":"Spooner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanna M.","family":"Pretzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki M.","family":"Zacharias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1638-1445","authenticated-orcid":false,"given":"Surena F.","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.09.005_b0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euros.2026.09.005_b0010","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.juro.2012.05.079","article-title":"Urothelial carcinoma of the bladder and the upper tract: disparate twins","volume":"189","author":"Green","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.09.005_b0015","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/1078-0432.CCR-18-2039","article-title":"Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma","volume":"25","author":"Audenet","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euros.2026.09.005_b0020","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.euros.2026.09.005_b0025","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.euf.2020.08.001","article-title":"Comprehensive genomic profiling of upper-tract and bladder urothelial carcinoma","volume":"7","author":"Necchi","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euros.2026.09.005_b0030","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","article-title":"Genomic characterization of upper tract urothelial carcinoma","volume":"68","author":"Sfakianos","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.09.005_b0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137141","article-title":"Molecular analysis of upper tract and bladder urothelial carcinoma: results from a microarray comparison","volume":"10","author":"Sanford","year":"2015","journal-title":"PLOS One"},{"key":"10.1016\/j.euros.2026.09.005_b0040","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.09.005_b0045","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.euf.2024.04.001","article-title":"Biomarkers of response to anti-NECTIN4 antibody-drug conjugate enfortumab vedotin in urothelial cancer","volume":"10","author":"Kl\u00fcmper","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euros.2026.09.005_b0050","first-page":"28989","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Onstage"},{"key":"10.1016\/j.euros.2026.09.005_b0055","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/j.eururo.2024.06.023","article-title":"Membranous expression of target protein is required for ADC response in urothelial cancer","volume":"87","author":"Clumper","year":"2024","journal-title":"Eura Urol"},{"key":"10.1016\/j.euros.2026.09.005_b0060","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.09.005_b0065","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2026.09.005_b0070","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population\u2010based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euros.2026.09.005_b0075","doi-asserted-by":"crossref","unstructured":"Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors. WHO classification of tumours of the urinary system and male Genital organs. ed. 4. Lyon, France: IARC; 2016.","DOI":"10.1016\/j.eururo.2016.02.029"},{"key":"10.1016\/j.euros.2026.09.005_b0080","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"Von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euros.2026.09.005_b0085","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.3390\/cancers17213410","article-title":"Tissue factor expression in penile squamous cell carcinoma: a potential marker of HPV-independent disease","volume":"17","author":"Jackson","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euros.2026.09.005_b0090","first-page":"716","article-title":"Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies","volume":"109","author":"McCarty","year":"1985","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.euros.2026.09.005_b0095","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euros.2026.09.005_b0100","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of Nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.euros.2026.09.005_b0105","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1186\/s12885-022-10076-7","article-title":"Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer","volume":"22","author":"Jeon","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euros.2026.09.005_b0110","doi-asserted-by":"crossref","first-page":"22498","DOI":"10.1038\/s41598-022-27093-y","article-title":"Correlation of TROP-2 expression with clinical\u2013pathological characteristics and outcome in triple-negative breast cancer","volume":"12","author":"Izci","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.euros.2026.09.005_b0115","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1186\/s12885-025-15042-7","article-title":"Comparison of molecular profiles (Nectin-4 and TROP-2) in upper tract urothelial carcinoma with a positive history of urinary bladder cancer vs. UTUC only in the era of ADCs","volume":"25","author":"Kanaan","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euros.2026.09.005_b0120","doi-asserted-by":"crossref","DOI":"10.1002\/2056-4538.70077","article-title":"Expression of Nectin\u20104 and Trop\u20102 in upper tract urothelial carcinoma: implications for biomarker\u2010driven antibody\u2010drug conjugate therapy","volume":"12","author":"Shi","year":"2026","journal-title":"J Pathol Clin Res"},{"key":"10.1016\/j.euros.2026.09.005_b0125","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s00345-026-06250-2","article-title":"TROP2 expression is associated with early stage and favorable prognosis in upper tract urothelial carcinoma","volume":"44","author":"Kobayashi","year":"2026","journal-title":"World J Urol"},{"key":"10.1016\/j.euros.2026.09.005_b0130","article-title":"Nectin-4 positivity in genitourinary malignancies: a systematic review","volume":"8","author":"Crupi","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euros.2026.09.005_b0135","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.3390\/ijms21155390","article-title":"Expression of Nectin-4 and PD-L1 in upper tract urothelial carcinoma","volume":"21","author":"Tomiyama","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euros.2026.09.005_b0140","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00428-025-04164-9","article-title":"Nectin-4 expression in upper and lower tract urothelial carcinoma: correlation with early-stage disease and prognostic relevance","volume":"488","author":"Kobayashi","year":"2025","journal-title":"Virchows Arch"},{"key":"10.1016\/j.euros.2026.09.005_b0145","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/his.15130","article-title":"Associations of TACSTD2\/TROP2 and NECTIN-4\/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts","volume":"84","author":"Bahlinger","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.euros.2026.09.005_b0150","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bju.16643","article-title":"Spatial distribution and subtype\u2010specific expression patterns of Nectin\u20104 in muscle\u2010invasive bladder cancer","volume":"136","author":"Olah","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2026.09.005_b0155","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s00280-025-04783-8","article-title":"Clinical relevance of Nectin-4 downregulation and biological changes caused by cytotoxic chemotherapy in bladder cancer","volume":"95","author":"Miyake","year":"2025","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.euros.2026.09.005_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.154072","article-title":"Tumor expression of Nectin-1-4 and its clinical implication in muscle invasive bladder cancer: an intra-patient variability of Nectin-4 expression","volume":"237","author":"Miyake","year":"2022","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.euros.2026.09.005_b0165","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1158\/1078-0432.CCR-23-3924","article-title":"Sacituzumab govitecan demonstrates efficacy across tumor Trop-2 expression levels in patients with advanced urothelial cancer","volume":"30","author":"Loriot","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 6","key":"10.1016\/j.euros.2026.09.005_b0170","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1200\/JCO.2023.41.6_suppl.545","article-title":"Prediction of response to neoadjuvant chemotherapy of patients with muscle invasive bladder cancer by molecular subtyping and antibody drug conjugate target gene quantitation: preview of Bladder BRIDGister","volume":"41","author":"Wirtz","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266616832602344X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266616832602344X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:29:51Z","timestamp":1793294991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266616832602344X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":34,"alternative-id":["S266616832602344X"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.09.005","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of NECTIN-4 and TROP-2 in Resected Upper Tract Urothelial Carcinoma with and Without Preoperative Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}